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ABSTRACT






Biological pathways of sclerostin
Sclerostin (scl) is a 22-kD osteocyte-specific glycoprotein and the gene product of SOST [1]. Scl acts as an inhibitor of the wingless-type mouse mammary tumor virus integration site (Wnt) -catenin pathway [2]. Wnt-β-catenin signaling participates in multiple physiologic pro​cesses crucial to embryonic development and tissue homeostasis [2]. It is increasingly acknowledged that the Wnt-β-catenin signaling pathway plays an important role in skeletal development and maintenance of bone mass [3].
Wnt-β-catenin signaling is initiated by binding of Wnt ligands to the dual receptor complex including frizzled protein and the low-density lipoprotein receptor-related protein 5 or 6 (LRP5/6). This interaction results in inactivation of the multiprotein β-catenin “destruction com​plex”, thus relieving the central signaling mediator β-catenin from its constitutive proteosomal degradation. β-catenin subsequently accu​mulates in the cytoplasm and translocates into the nucleus, where it associates with transcription factors to control target gene transcription [4]. Wnt-β-catenin signaling pathway is tightly regulated by several inhibitors, among which Dickkopf-related protein 1 (DKK1) and scl. Scl specifically inhibits Wnt-β-catenin pathway by binding to LRP5/6 [5]. In an animal model with a loss-of-function mutations of LRP5/6, a decrease in bone mineral density (BMD) is observed, whereas gain-of function mutations of LRP5 lead to increased BMD [3,4].
Scl is produced by osteocytes [6]. Osteocytes are former osteoblasts that have been buried in the bone matrix. Osteocytes are able to sense mechanical loading and secrete local factors that cause bone resorption and formation [7]. In this context, the role of scl on bone metabolism is nicely described in animal models with unloaded bone. In such models, scl concentrations are dramatically increased. Scl, secreted by osteocytes, is thus presented as the missing link between the absence of mechanical stress and the impaired bone formation [8]. At the opposite, when osteocytes detect mechanical stress, the secretion of scl is de​creased, releasing inhibition on the precursors to osteoblasts, and thus will initiate new bone formation [8]. In the same view, injection of scl antibodies in rats increased trabecular and cortical bone mass and induced a strong increase in bone formation rate [9]. The impact of scl on bone is also described by its action in other pathways: interaction with bone morphogenic protein (BMP) [10] and the osteoprotegerin - re​ceptor activator of nuclear factor k β - receptor activator of nuclear factor k p ligand (OPG-RANK-RANKL) system [11,12].
Determinants of sclerostin
Several clinical and biological factors are identified as determinants of scl secretion. \h  lists major factors affecting either scl expression in bone and/or plasma scl concentrations. The role of renal function will be discussed in details in a dedicated paragraph. Briefly, age and body mass index (BMI) increase scl production [13,14]. Hormones also regulate scl production: BMP stimulates secretion, whereas parathyroid hormone (PTH) [15] suppresses the expression of scl [16]. Fibroblast growth factor 23 (FGF23) impacts the production of scl as well as calcitriol (1,25-dihydroxyvitamin D) and serum phosphate levels [17,18]. Scl is modulated also by clinical conditions. An upregulation of its concentration is seen in diabetic patients and after parathyroidectomy [19]. Circulating Wnt signaling inhibitors may also be modulated by glucocorticosteroids (GCs) [3] or estrogens level [20].

Table 1. Determinants of sclerostin expression.
Determinant	Impact	Experimental evidence	Clinical evidence	Mechanisms
Age	Positive	[8]	[13,14]	Unknown but might be an age-related reduction of daily activity, and results in muscles generating fewer stimuli and lower mechanical stress on boneAlternatively, it may result from a decreased bone mass, c.q. decreased osteocyte number
PTH	Negative	[15,21,22]	[16,23,24]	Direct action of PTH promoting Wnt-β-catenin pathwayDirect impact on osteoblast differentiation
Phosphorus	Positive	[25,26]	[27]	Through increase of FGF23Changes in SOST expression through a PTH-independent mechanism
Calcitriol	Negative	[18,28,29]	[30]	•      Decreased activation of 1α-hydroxylase
Estrogens	Negative	[31]	[13]	•    Cytokine TNFα (from T cells under an estrogen deficient condition) increased sclerostin
Diabetes	Positive	[32]	[33]	Wnt-β-catenin pathway implicated in pancreatic islet development and the production of incretin hormoneRole in Wnt signaling in hepatic glucose metabolism by acting through the same pathways





Sclerostin and bone metabolism
Mutations of the SOST gene lead to rare genetic diseases char​acterized by high bone mass, such as Sclerosteosis or Van Buchem disease [34]. The fundamental role of scl in humans is well illustrated by the clinical effect of anti-scl antibody (Romosozumab) in large randomized clinical trials including osteoporotic women where this therapy leads to benefit in terms of BMD and even reduction of fractures [35-37].
The potential role of scl as a plasma biomarker to assess BMD is more difficult to apprehend. In the general or osteoporotic population, serum scl levels is positively correlated with BMD in most studies [13,28-42] but not in all [14,43]. Beyond discrepancies between stu​dies, the positive association between scl and BMD is counterintuitive. Different hypotheses are found in the literature. Increased scl con​centrations could reflect the number of osteocytes (higher number when BMD is higher), or a high scl concentration may be associated with low bone turnover, which is repeatedly associated with increased BMD, partly as a consequence of accentuated secondary mineralization. Finally, the “brake” hypothesis can be mentioned: when BMD is low (for any possible reason), the concentration of scl is lower than when BMD is “normal” because its inhibitory effect on bone formation is not required. All these explanations remain still speculative. In the general and osteoporotic populations, the role of scl as a bone biomarker is still not fully understood, and thus actually not recommended in clinical practice.(see \h )
Sclerostin within the chronic kidney disease spectrum
Sclerostin and chronic kidney disease
The interpretation of plasma scl concentrations in chronic kidney disease (CKD) patients is still more challenging. It is demonstrated that scl concentrations increase as glomerular filtration rate (GFR) decreases [27]. Whether this is due to reduced renal clearance, increased skeletal production, or even an extraskeletal production is still a subject of debate [44]. In end stage renal disease (ESRD) patients, dialysis modality may also influence serum scl level [45].
A bunch of work attempts to demonstrate the potential role of Wnt signaling in Chronic Kidney Disease and Mineral Bone disorder (CKD- MBD) process. CKD-MBD defined the overall 1°) skeletal alteration (either abnormalities in bone turnover (T), mineralization (M), or bone volume or strength (V)), 2°) mineral disorders and 3°) soft tissue or vascular calcifications (VCs) appearance with the progression of CKD [46]. Those abnormalities are critical contributors of the high cardio​vascular (CV) morbidity and mortality and fracture rate observation in this population.
The impact of scl in CKD-MBD development is well described in the jck mouse model, a genetic model of polycystic kidney disease that exhibits progressive renal failure. An increase in bone scl expression is observed in the early stages of renal disease [47]. In another CKD an​imal model of adynamic bone disease (ABD), high dietary phosphate intake is associated with a high osteocyte expression of SOST [25]. Moe et al. [22] observed improved bone properties in an animal model of progressive CKD treated with anti-scl antibodies, however, only when the PTH levels is low.
In CKD patients, circulating scl levels are negatively correlated with serum PTH [48-50]. PTH downregulates scl expression in osteocytes, and this interaction represents an important aspect of how PTH sti​mulates bone metabolism [51]. It is suggested that scl could contribute to the well-known PTH resistance in CKD [52], which could cause and/ or aggravate ABD [53]. Therefore, blocking scl is a valuable research target in treatment of low-bone turnover [4].
In vivo data have implicated the Wnt signaling pathway in the de​velopment of VCs especially in CKD models. Indeed, an upregulation of sclerostin mRNA is show in calcified aortic valve tissue of haemodia​lysis (HD) patients [54]. It is hypothesized that scl is involved in the pathogenesis of the calcification paradox which refers to disease states characterized by the coincidence of skeletal demineralization and vas​cular mineralization. This calcification paradox is one of the char​acteristic features of CKD-MBD [55]. \h  shows the possible effect of scl into the VC process. Some controversy exists over the role of scl into the progression of atherosclerosis and in VC development, either in the general [56] or in the CKD population [57].
Sclerostin and bone metabolism in CKD/ESRD patients




Fig. 1. (a) Wnt canonical signalling pathway in osteoblast and (b) sclerostin mechanism of action. β-cat: Beta-catenin; DC: destruc​tion complex; LEF: Lymphoid enhancing factor; LRP5/6: Low density lipoprotein re​ceptor related protein 5/6; TCF: T-cell factor; Wnt: Wingless-type mouse mammary tumor virus integration site family member.

Many observa​tional and transversal studies, without bone biopsies, demonstrate a negative correlation between scl concentrations and PTH [38,59,60] or other biomarkers of bone formation [49,61]. However, in a longitudinal study analyzing the variation of PTH and bone biomarkers in dialysis patients over a 1-year period, no correlations between scl variations and PTH or bone biomarkers variations are found [62]. The real role of scl as a biomarker of bone turnover in CKD patients remains unclear.
However, by its mechanism of action, scl could be more a biomarker of bone density rather than a biomarker of bone turnover. For instance, in a transversal French study of HD patients, serum scl concentration is higher in the higher BMD tertile [63]. In a 181 Japanese HD patients cohort, scl is also positively associated with BMD [61]. A study on 89 PD patients demonstrates a positive association in multiple regression analysis, between serum scl levels and BMD, but the marginal asso​ciation between scl and PTH is surprising in this study [64]. In another transversal study including 518 ESRD patients, the same positive cor​relation is observed between scl and BMD [65]. To the best of our knowledge, only one cohort studied scl in a longitudinal design, with eighty-one incident HD patients, and demonstrates an high scl levels at baseline to be predictive of bone loss over a 1-year period [66].






Table 2. Studies on correlation between sclerostin and vascular calcifications development.

Authors and reference	Patients (n) Renal status	Type of calcifications detection and sclerostin assay	Association between sclerostin and VC
Claes et al. \h 	154CKD 1 - 5	AAC by lateral X-rayTECOmedical	Univariate analysis: positive associationMultivariate analysis: negative association after adjustment for age, diabetes, CV history, hypertension, BMI, eGFR, CRP
Morena et al. \h 	241CKD 2 - 5	CAC by CT scanTECOmedical	Univariate analysis: positive associationMultivariate analysis: positive association after adjustment for age, gender, diabetes, BMI and smoking
Lv et al. [75]	97CKD 3 - 4	AAC by CT scanBiomedica	Univariate analysis: positive associationMultivariable analysis: positive association after adjustment for age and eGFR
Brandenburg et al. \h 	67HD patients	CAC by CT scanTECOmedical	Univariate or multivariate analysis: no associationBut high sclerostin level associated with aortic valvular calcification in univariate and multivariate model
Delanaye et al. \h 	164HD patients	AAC by CT scanTECOmedical	Univariate analysis: no associationMultivariable analysis: negative association
Yang et al. [73]	125HD patients	Aortic calcification by     X-rayR&D Systems	•        Univariate analysis: negative association
Jean et al. \h 	207HD patients	AAC by lateral X-rayTECO medical	•        Univariate analysis: negative association
Qureshi et al. \h 	89HD patients	CAC by CT scanR&D Systems	Univariate analysis: positive associationMultivariable analysis: no association after adjustment for age, gender and diabetesBut in multivariate analysis for calcification detected in the tissue: positive association after adjustment for age, gender
Bruzzese et al. [76]	• 21• HD patients	CAC by CT scanTECO medical	•        Univariate analysis: no association
Wang et al. [77]	• 161• CKD 3 - 5D (HD    and PD)	AAC by lateral X-rayCUSABIO	Binary logistic regression analysis: positive associationBut lower sclerostin level when AAC are moderate to severe





In non-dialysis CKD patients, high circulating scl levels correlates with higher BMD and better bone microarchitecture \h . A study in​cluding CKD stage 3b and 4 patients demonstrates that scl is positively associated with BMD at the hip and at the lumbar spine \h . The po​tential role of scl as a biomarker of BMD should be confirmed by future analyses.


Sclerostin and vascular calcifications in CKD/ESRD patients
The potential role of scl as a biomarker of VCs is difficult to estab​lish. Indeed, results in the literature are quite discrepant: some authors found positive\h or negative associations\h , such as​sociation could vary in the same study when univariate or multivariate analyses are considered. The \h  summarized the data on the as​sociation between scl and VCs. In addition, carotid intima-media thickness (CIMT) measurement, could detect early atherosclerosis de​velopment compared to the late assessment of VC through CT scan. A study on CKD population demonstrates that serum scl level is not cor​relate with CIMT, arguing that scl is rather link to the formation of calcification in CKD patients rather than atherosclerotic development \h . Further studies are needed to confirm this hypothesis.
Sclerostin and survival outcomes in CKD/ESRD patients
Studies evaluating the association between circulating scl con​centrations and mortality in CKD have yielded inconsistent results as well. Indeed, some investigators report high circulating scl levels to be associated with better survival\h whereas others report an inverse [76,79] or no\h association. These conflicting data may be explained by case-mix, use of different assays, and different competing factors used in multivariate analysis. Most studies on scl and survival outcomes are summarized in \h .
A meta-analysis has been performed regarding the association between scl concentrations and CV or all-cause mortality. The authors concluded that scl was not associated with mortality, but the number of studies included was low, and the analysis revealed a high hetero​geneity, meaning that the results have to be taken with caution [80].
Analytical methods for sclerostin measurement







Table 3. Sclerostin ' studies associated with cardio-vascular or all-cause mortality outcomes.
Authors and reference	Patients (n) Renal status	Sclerostin assayand Follow-up	Outcomes
Kanbay et al. [79]	• 173	• Biomedica	•   Univariate analysis: positive association with CV death and all-cause mortality
	• CKD 3 - 5	• 26 months	• Multivariate analysis: positive association with CV death after adjustment for eGFR, markers of endothelial dysfunction, or other CKD-MBD parameters but no association with all-cause mortality
Desjardins et al. [81]	140CKD 2 - 5D	Immuno-diagnostik AG18 months	• Univariate and multivariate analysis: positive association with all-cause mortality after adjustment for age, IL-6, phosphate, CKD stage and p-cresyl sulphate
Viaene et al.\h 	• 100	• Biomedica	• Univariate analysis: no association with survival
	• HD patients	• 21 months	Multivariate analysis: positive association with survival after adjustment for age and genderMultivariate analysis: no association with survival after adjustment for age, gender, diabetes, dialysis vintage, CRP and bALP
Gonçalves et al. [78]	91HD patients	TECOmedical120 months	• Univariate and multivariate analysis: positive association with all-cause mortality after adjustment for age, gender, diabetes, creatinine, FGF23
Nowak et al. [82]	239HD patients	TECOmedical48 months	• Univariate and multivariate analysis: no association with CV or all cause-mortality
Drechsler et al.\h 	673HD and PD patients	TECO at 3months ofdialysis initiation48months	• Univariate and multivariate analysis: negative association with CV mortality after adjustment for age, gender, GFR, BP, albumin, hemoglobin, calcium, PTH, ALP
Delanaye et al.\h 	164HD patients	TECOmedical48 months	• Univariate analysis: no association with mortality
Jean et al.\h 	207HD patients	TECOmedical30 months	• Univariate and multivariate analysis: negative association with all-cause mortality after adjustment for age, dialysis vintage, cardiac disease, peripheral vascular disease, stroke, kauppila score
Chen et al. [83]	84HD patients	R&D61.2 months	Univariate and multivariate analysis: positive association with all-cause mortality after adjustment for age, albumin, uric acid, sclerostin, CIMT, diabetes and history of CV diseaseUnivariate and multivariate analysis: no association with CV death

bALP: bone Alkaline Phosphatase; BP: Blood Pressure; CI: Confidence Interval; CIMT: Carotid Intima-Media Thickness; CKD-MBD: Chronic Kidney Disease and Bone and Mineral Disorder; CRP: C-reactive Protein; CV: Cardio-Vascular; eGFR: estimated Glomerular Filtration Rate; ESRD: End Stage Renal Disease; FGF23: Fibroblast Growth Factor 23; HD: Haemodialysis; HR: Hazard ratio; IL: Interleukin; PTH: Parathyroid Hormone.
The choice of the assay could also influence conclusions on the impact of HD versus HDF on scl concentrations. Indeed, HDF is associated with a greater scl decline after dialysis session when measured by TE and BM assays, but this decline was not observed when scl is measured with the RD or MSD assays. Our clinical knowledge about the role of scl in CKD and dialysis patients is obviously influenced by the assay used to measure it. We actually do not know which assay is preferable to be used, waiting for a reference method like mass spec​trometry. None of the assays used can currently be considered as a reference method, and thus all results have to be interpreted with caution.
Conclusions
Scl could be a promising biomarker in assessing bone health in CKD patients, but it is not clear whether it has any true added value com​pared with existing bone biomarkers in predicting bone turnover and/ or bone density. Its clinical utility for predicting hard clinical end points is still unknown. Measuring serum scl in clinical routine remains diffi​cult and its interpretation is still challenging, and thus up-to-now not recommended. Further studies, both analytical and clinical, should help to better interpret the scl results.
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